| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
HLA-C*03:04:01 and HLA-B*15:18:01 but not HLA-DQA1*05 associated with anti- tumor necrosis factor antibody formation in Taiwanese inflammatory bowel disease patients
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Meng-Tzu Weng, Chi-Yuan Yao, Wei-Chen Lin, Sheng-Kai Lai, Chien-Chih Tung, Chun-Ying Wang, Jau-Min Wong, Pei-Lung Chen and Shu-Chen Wei |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Science and Technology, Taiwan |
MOST 111-2314-B-002-226 |
| National Taiwan University Hospital, Hsin-Chu Branch |
112-BIH017 |
| The Liver Disease Prevention and Treatment Research Foundation, Taiwan |
|
|
| Corresponding Author |
Shu-Chen Wei, MD, PhD, Professor, Department of Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei 100, Taiwan. shuchenwei@ntu.edu.tw |
| Key Words |
Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Anti-tumor necrosis factor therapy; Anti-drug antibodies; Human leukocyte antigen genotype |
| Core Tip |
The development of anti-drug antibodies (ADA) compromises the effectiveness of biologic therapies in treating inflammatory bowel disease (IBD). In European inflammatory bowel disease patients receiving anti-tumor necrosis factor therapy, the human leukocyte antigen (HLA)-DQA1*05 allele has been strongly associated with increased ADA formation. However, this association does not appear to hold in Taiwanese patients. Instead, distinct HLA variants have emerged: HLA-C*03:04:01 is linked to ADA formation in those treated with infliximab, while HLA-B*15:18:01 is associated with immunogenicity to adalimumab. Notably, in the Taiwanese cohort, HLA-DQA1*05 does not predict ADA development during anti-tumor necrosis factor treatment. |
| Publish Date |
2025-11-06 08:56 |
| Citation |
Weng MT, Yao CY, Lin WC, Lai SK, Tung CC, Wang CY, Wong JM, Chen PL, Wei SC. HLA-C*03:04:01 and HLA-B*15:18:01 but not HLA-DQA1*05 associated with anti- tumor necrosis factor antibody formation in Taiwanese inflammatory bowel disease patients. World J Gastroenterol 2025; 31(41): 111745 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i41/111745.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i41.111745 |
